420 related articles for article (PubMed ID: 32655561)
1. Anti-dengue Vaccines: From Development to Clinical Trials.
Pinheiro-Michelsen JR; Souza RDSO; Santana IVR; da Silva PS; Mendez EC; Luiz WB; Amorim JH
Front Immunol; 2020; 11():1252. PubMed ID: 32655561
[No Abstract] [Full Text] [Related]
2. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Neutralizing Dengue Virus B Cell Epitopes and Protective T Cell Epitopes With Those in Three Main Dengue Virus Vaccines.
Pinheiro JR; Camilo Dos Reis E; Souza RDSO; Rocha ALS; Suesdek L; Azevedo V; Tiwari S; Rocha BGS; Birbrair A; Méndez EC; Luiz WB; Amorim JH
Front Immunol; 2021; 12():715136. PubMed ID: 34489965
[TBL] [Abstract][Full Text] [Related]
4. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
[TBL] [Abstract][Full Text] [Related]
5. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
6. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Galula JU; Salem GM; Chang GJ; Chao DY
Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
[TBL] [Abstract][Full Text] [Related]
7. Vaccines and immunization strategies for dengue prevention.
Liu Y; Liu J; Cheng G
Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
[TBL] [Abstract][Full Text] [Related]
8. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
9. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
10. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
11. Dengue vaccines: challenges, development, current status and prospects.
Ghosh A; Dar L
Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
13. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
14. Human CD4
Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003.
Waickman AT; Friberg H; Gargulak M; Kong A; Polhemus M; Endy T; Thomas SJ; Jarman RG; Currier JR
Front Immunol; 2019; 10():1778. PubMed ID: 31417556
[TBL] [Abstract][Full Text] [Related]
16. Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1.
Friberg H; Martinez LJ; Lin L; Blaylock JM; De La Barrera RA; Rothman AL; Putnak JR; Eckels KH; Thomas SJ; Jarman RG; Currier JR
mSphere; 2020 Jan; 5(1):. PubMed ID: 31969476
[TBL] [Abstract][Full Text] [Related]
17. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
18. Live attenuated vaccine: the first clinically approved dengue vaccine?
Fink K; Shi PY
Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
[TBL] [Abstract][Full Text] [Related]
19. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
[TBL] [Abstract][Full Text] [Related]
20. Dengue: Status of current and under-development vaccines.
Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S
Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
